Annual revenue fell from KRW 223.4 billion in 2022 to KRW 197.6 billion in 2023 (down 11.5% YoY) and then rose to KRW 237.4 billion in 2024 (up 20.1% YoY) and KRW 280.3 billion in 2025 (up 18.1% YoY).
Revenue grew for two years in a row, from 2024 through 2025, and 2025 was the largest year of the 2022–2025 period while 2023 was the smallest.
Operating profit moved from KRW 6.18 billion in 2022 to an operating loss of KRW 10.8 billion in 2023 (a turn to loss from the prior year), then to operating profit of KRW 2.29 billion in 2024 (a turn to profit), and back to an operating loss of KRW 547 million in 2025 (a turn to loss).
The operating margin was 2.8% in 2022, -5.5% in 2023, 1.0% in 2024 and -0.2% in 2025, so revenue growth did not translate into margin recovery.
Net income attributable to controlling shareholders went from KRW 44.1 billion in 2022 to a loss of KRW 13.6 billion in 2023, a profit of KRW 1.45 billion in 2024, and a loss of KRW 12.3 billion in 2025.
Net income including non-controlling interests was a loss of KRW 14.3 billion in 2025, a larger loss than the parent-shareholder figure.
A ThinkPool research summary attributed the 2025 revenue increase to expanded DUV pellicle sales and new customers, and said the widened net loss mainly reflected equity-method losses from associates.
By quarter, revenue was KRW 65.5 billion in the third quarter of 2025, KRW 89.3 billion in the second quarter of 2026 and KRW 91.2 billion in the third quarter of 2026, rising for two consecutive quarters from the second quarter of 2026.
Operating profit was KRW 1.42 billion in the first quarter of 2026 (a turn to profit), KRW 9.62 billion in the second quarter (up 577.3% QoQ), and an operating loss of KRW 3.68 billion in the third quarter (a turn to loss QoQ).
Net income attributable to controlling shareholders was a profit of KRW 7.32 billion in the second quarter of 2026 and a loss of KRW 7.9 billion in the third quarter.
The net loss attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totaled KRW 6.01 billion.
The debt-to-equity ratio rose from 60.6% in 2022 to 122.9% in 2025, with total equity of KRW 242.3 billion at year-end 2025 (of which KRW 241.3 billion attributable to controlling shareholders) and total liabilities of KRW 297.8 billion.
Operating cash flow turned positive at KRW 14.1 billion in 2025 after KRW -5.39 billion in 2024. FnGuide's company summary notes that a rise in one-off costs is limiting profitability.